ISDS stands for investor-state dispute settlement, a legal mechanism that allows foreign companies to sue governments before international arbitration panels. If a country passes a law or policy that a foreign investor believes unfairly harms their investment, ISDS lets that investor bypass the country’s own courts and take the dispute to a panel of international arbitrators. These provisions are embedded in thousands of trade and investment agreements worldwide, and they’ve become one of the most contentious features of modern international trade.
How ISDS Works
ISDS provisions appear in bilateral investment treaties and free trade agreements between countries. When a government signs one of these agreements, it typically promises to protect foreign investors from discriminatory, unfair, or arbitrary treatment. If a foreign company believes a government has broken those promises, it can file a claim for financial compensation.
The case doesn’t go to a domestic court. Instead, it’s heard by a tribunal of three arbitrators, usually appointed jointly by the investor and the government. The primary forum for these cases is the International Centre for Settlement of Investment Disputes (ICSID), which is affiliated with the World Bank. The arbitrators review the evidence, decide whether the government violated its treaty obligations, and can order the government to pay damages. In many cases, these awards are final and cannot be appealed.
Why ISDS Is Controversial
Supporters argue that ISDS protects companies from genuinely unfair government behavior, like seizing a factory without compensation or singling out a foreign company for punitive regulations. That protection, they say, encourages international investment by giving companies confidence that they’ll be treated fairly.
Critics see it differently. They argue ISDS gives multinational corporations an extraordinary power: the ability to challenge laws that governments pass to protect public health, safety, or the environment. When a company files or even threatens an ISDS claim, it can pressure governments to weaken, delay, or abandon regulations entirely. Trade and health researchers call this effect “regulatory chill,” where a government delays, compromises, or abandons legitimate public interest regulation to avoid the cost and risk of an international dispute.
The Tobacco Cases
The most high-profile examples of ISDS in action involve tobacco regulation. In 2010, Uruguay passed two public health measures: one requiring graphic health warnings covering 80% of the front and back of cigarette packs, and another limiting each cigarette brand to a single variant, eliminating names like “gold,” “silver,” or “blue” that replaced misleading terms like “light” and “mild.” Philip Morris filed an ISDS claim against Uruguay, arguing these rules destroyed the value of its trademarks.
The arbitration panel dismissed all of Philip Morris’s claims in July 2016 and ordered the company to pay $7 million of Uruguay’s legal costs. But the case still cost Uruguay roughly $10 million in legal fees, and the total costs for both sides exceeded $28 million, in a dispute where Philip Morris had originally claimed just $25 million in damages. For a small country like Uruguay, the financial burden of defending its own health laws was significant even in victory.
Australia faced a similar challenge after introducing plain packaging laws that stripped tobacco products of nearly all branding. That case also failed, and in response, Australia and Singapore became among the first countries to write explicit exclusions into their investment agreements, stating that no ISDS claim could be brought over tobacco control measures. South Africa reportedly delayed progress on its own plain packaging regulation by about two years while waiting to see how Australia’s cases turned out, a clear example of regulatory chill in practice.
The Pharmaceutical Patent Fight
ISDS disputes aren’t limited to tobacco. In 2012, the American pharmaceutical company Eli Lilly filed a $500 million claim against Canada after Canadian courts invalidated patents on two of its drugs: Strattera, used for ADHD, and Zyprexa, an antipsychotic. Those court rulings allowed generic companies to market lower-cost versions of both drugs.
Eli Lilly argued that Canada’s patent standards had undergone a “radical change” that unfairly stripped its patent protections. Canada required patent holders to prove their inventions were genuinely useful, and Lilly’s patents didn’t meet that bar. The ICSID tribunal sided with Canada, finding that Lilly had not demonstrated any fundamental change in Canadian patent law and that the Canadian court decisions were neither arbitrary nor discriminatory.
Legal experts noted the stakes: if Lilly had won, it could have pressured countries to weaken their patent standards, potentially limiting access to affordable generic drugs. The ruling was widely seen as affirming that countries can shape their patent laws to suit national needs, a signal particularly relevant for countries like Brazil, India, and South Africa, where access to generic medicines is critical.
Transparency and Reform
One longstanding criticism of ISDS is that it operates behind closed doors. The original rules governing arbitration at ICSID stated that awards could not be published without consent from both parties. Hearings were held privately. The public often had no way to know that a case was even happening, let alone follow its progress.
This has changed gradually. ICSID revised its rules in 2006 to allow publication of case documents and open hearings with party consent, and to permit submissions from outside groups with relevant expertise. In 2022, the rules were amended further: arbitral awards and decisions are now published within 60 days unless a party explicitly objects. Hearing recordings, transcripts, and written submissions can also be made available. The United Nations trade law commission developed its own transparency rules covering document publication, open hearings, and third-party submissions.
These reforms address some concerns, but broader questions remain. Several countries have moved to limit or remove ISDS from their trade agreements altogether. The United States-Mexico-Canada Agreement, which replaced NAFTA, significantly scaled back ISDS provisions. Internationally, treaty negotiations increasingly focus on balancing investment protection with governments’ ability to regulate in the public interest, reflecting a growing recognition that the original system tilted too far in one direction.
Other Meaning of ISDS
In public health circles, ISDS can also stand for the International Society for Disease Surveillance, an organization focused on best practices in tracking and monitoring disease outbreaks. Its membership includes surveillance programs worldwide, from well-resourced systems to those in resource-limited settings. If you searched “ISDS” in the context of epidemiology or disease tracking, that’s the organization you’re looking for. In most policy and trade discussions, though, ISDS refers to investor-state dispute settlement.